Abstract: The present invention produces affinity ligands that make it possible to increase the purity of antibodies themselves, which is the main purpose of affinity purification, and, further, to improve the selectivity for antibody monomers and thereby reduce the load of removing antibody multimers on downstream purification steps. The present invention provides new affinity ligands which are modified proteins obtained by introducing a mutation into a protein to increase the number of acidic amino acids in the amino acid sequence of the protein; methods for designing the modified proteins; methods for producing the modified proteins; and affinity separation matrices containing the modified proteins as ligands immobilized therein.

Abstract: A multimeric immunoglobulin-binding protein having improved properties as an affinity ligand for affinity chromatography, and an insoluble support inmmobilizing such a multimer. The immunoglobulin-binding protein is represented by the formula: (R1)n-(R2)m, or (R2)m-(R1)n. R2 is an immunoglobulin-binding domain including an amino acid residue that covalently bonds to an insoluble support upon immobilization reaction with the insoluble support, and R1 is an immunoglobulin-binding domain without containing an amino acid residue the presence of which in the sequence compared to when it is absent in the sequence reduces the immunoglobulin-binding activity of the support yielded by the immobilization reaction. The immunoglobulin-binding protein satisfies: (1) n is an integer of 5 to 9; (2) m is an integer of 1 or 2; (3) the n (R1) domains may or may not have the same sequence; and (4) the total number of domains (n+m) is 6 to 10.

Abstract: Described are methods and products useful for identifying subjects with Mycobacterium avium subspecies paratuberculosis (MAP). A number of protein antigens secreted into culture filtrate by MAP are identified and binding proteins selective for these antigens are demonstrated to be useful for detecting subjects with MAP infections including subjects with Johne's disease.

Abstract: The present invention relates to novel polypeptides comprising an ice-binding capability resulting in an ice crystal formation and/or growth reducing or inhibiting activity. The present invention also relates to an edible product and to a solid support comprising the novel polypeptide. Furthermore, the present invention also relates to a method for producing the novel polypeptide and to different uses of the novel polypeptide.

Abstract: The present invention provides a dialysis-free process for the generation of aqueous regenerated silk fibroin solutions. A degumming reactor is presented that enables scalable batch degumming. As well, the use of diafiltration and desalting columns are introduced for the purification of silk fibroin solutions, representing a set of techniques that isolate solubilized silk fibroin through the efficient removal of a solubilization agent while implicitly availing the increase in concentration of otherwise dilute aqueous silk fibroin solutions.

Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in treatment naïve mammals, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a naïve mammal in need thereof who had not previously been treated for the condition.

Abstract: The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease.

Abstract: The present invention provides a composition of homogeneously glycosylated GM-CSF or a homogeneously glycosylated fragment thereof, wherein each molecule of GM-CSF or fragment thereof has the same glycosylation pattern, and for a given glycosylation site each molecule of GM-CSF or fragment thereof has the same glycan. The present invention further provides methods of making and using such compositions.

Abstract: The present invention relates to a water-soluble expression and a purification method of a human granulocyte colony-stimulating factor (hGCSF) recombinant protein having biological activities using an N-terminal tag, and provides a recombinant expression vector containing a solubility enhancing tag and a hGCSF gene. In addition, provided are: a recombinant microorganism transformed with the recombinant expression vector; a method for producing a hGCSF recombinant protein (rhGCSF); and a rhGCSF produced by the production method.

Abstract: The present invention relates to interleukin-4 receptor binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 receptor binding protein moiety joined to a pro-apoptotic Bcl-2 family member protein moiety.

Abstract: Provided herein are stabilized ?-CT polypeptides comprising an alpha-helical segment, and wherein the polypeptide is of Formula (I-1) or Formula (I-2): Rf—[XAA]s—XA1—XA2—XA3—XA4—XA5—XA6—XA7—XA8—XA9—XA10—XA11—XA12—XA13—XA14—[XAA]t—Re (I-1) Rf—[XAA]s—XC1—XC2—XC3—XC4—XC5—XC6—XC7—XC8—XC9—XC10—XC11—XC12—XC13—XC14—XC15—XC16—XC17—XC18—XC19—XC20—[XAA]t—Re (I-2) wherein the ?-CT polypeptide binds to the insulin receptor, and wherein the ?-CT polypeptide includes at least one staple (i.e. two cross-linked amino acids) and/or at least one stitch (i.e. three cross-linked amino acids). Further provided are insulin analogues including the stapled or stitched ?-CT polypeptides, pharmaceutical compositions thereof, methods of use, e.g., methods of treating a diabetic condition or complications thereof.

Abstract: The present invention provides a novel derivative of an analogue of human insulin, useful for the treatment of diabetes.

Abstract: Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.

Abstract: The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Abstract: The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies.

Abstract: Described herein are novel compositions comprising MT1 and/or MT2 modulators (i.e., inhibitors or activators), and methods using these agents for targeting different T-cell populations, for example, type 1 regulatory (Tr1) CD4+ cells and exhausted CD8+ T-cells cells. Aspects of the invention relate to inhibitors of MT1 and/or MT2 to increase the differentiation of CD4+ cell Trl1 CD4+ cells and increase in the activity of Tr1 cells, e.g., to increase IL-10 production. In alternative embodiments, MT1 and/MT1 inhibitors can be used to increase proliferation and/or activity of exhausted CD8+ T-cells and to decrease CD8+ T-cell exhaustion (e.g., decrease functionally exhausted or unresponsive CD8+ immune cells). Accordingly, aspects of the present invention relate to compositions and methods comprising inhibitors of MT1 and/or MT2 useful in the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune disease.

Abstract: A method of treating sarcopenia comprises administering to a subject a composition comprising an anti-AGE antibody. The method may also be used for preventing or delaying the onset of cataracts, preventing or delaying the onset of loss of adipose tissue, increasing health span, and preventing or delaying the onset of lordokyphosis.

Abstract: The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component C5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions. Also featured are therapeutic kits containing one or more of the solutions and a means for administering the solutions to a patient in need such a treatment.

Abstract: The present invention relates to compounds that bind to human vascular endothelial growth factor A (VEGFA) and human angiopoietin-2 (Ang2), and may be useful for treating angiogenic eye diseases, such as diabetic and other proliferative retinopathies, and for cancer, especially solid tumors driven by VEGFA and Ang2, including gastric, lung, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.

Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.

Abstract: The present invention provides bispecific molecule comprising: (i) a first antigen binding portion which specifically targets the synovial microvasculature of arthritis patients and which binds to the same epitope as an antigen binding polypeptide comprising the amino acid sequence shown as SEQ ID No 11; and (ii) a second antigen binding portion which binds tumour necrosis factor alpha (TNF-?). The present invention also relates to the use of such bispecific molecules in the prevention and/or treatment of arthritis.

Abstract: The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications.

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.

Abstract: The present invention provides for methods of producing human monoclonal antibodies to human nucleolin, cells producing such antibodies, and the antibodies themselves. Also provided are methods of using the antibodies in diagnosing and treating malignant and non-malignant diseases wherein cells that express nucleolin on the cell surface contribute to the pathophysiology of the disease.

Abstract: The present invention relates to methods of minimizing the aggregation of BiTE® molecules in solution. In one embodiment, a method of the invention is used to minimize the aggregation of BiTE® molecules in solution. In another embodiment, a method of the invention is used to minimize the aggregation of BiTE® molecules comprising a first and a second binding site specific for the CD3 and CD19 antigens, respectively, wherein said molecule is in solution. In a specific embodiment, the present invention provides methods to minimize the aggregation of the MT103™ BiTE® molecule in solution.

Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.

Abstract: The subject of the invention is the application of CXCL12 (Chemokine (C-X-C motif) Ligand 12) and IGFBP2 inhibitors for the treatment of diabetes mellitus associated pancreatic cancer. The core of this invention is the discovery that the chronically increased glucose levels (chronic hyperglycemia) could may an important role in the development of the pancreatic cancer and that the development of the pancreatic cancer due to chronic hyperglycemia or an already developed pancreatic cancer may be prevented/inhibited/delayed by the inhibition of CXCL12 and IGFBP2. In addition the subject of the invention is the production of inhibitors for the application as a treatment of diabetes mellitus associated pancreatic cancer and pharmaceutical drugs containing the inhibitors.

Abstract: Methods of treatment of diabetes are disclosed. These methods include administration of an inhibitor of chemokine XCL1, and administration of an inhibitor of XCL1 receptor XCR1. Inhibition of formation of CD103+ dendritic cells, inhibition of their migration into islets, or inhibition of function of CD103+ dendritic cells can be used to prevent, treat or manage diabetes.

Abstract: Provided herein are an exogenous antibody that binds selectively to a misfolded form of human FasR, and methods and uses for said antibody. Specifically disclosed is the antibody designated AMF 3a-118 which selectively binds the peptide represented by LHHDGQFCH (SEQ ID NO:2) and the antibody designated AMF 3d-19 which selectively binds the peptide represented by NSTVCEH (SEQ ID NO:5).

Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.

Abstract: Disclosed herein is a method for treating and/or preventing atrial fibrillation in a subject, comprising administering to the subject a pharmaceutical composition comprising an anti-CD44 neutralizing antibody or an antigen binding portion thereof which specifically binds to the amino-terminal domain of CD44. The anti-CD44 neutralizing antibody is a monoclonal antibody. The pharmaceutical composition further includes a pharmaceutically acceptable carrier.

Abstract: Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Abstract: The present invention relates to an ICOS binding protein, or antigen binding portion thereof that is an agonist human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more oft SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.

Abstract: A framework fragment derived from a chicken antibody, in which an amino acid at a particular position is replaced by cysteine, a heavy chain variable region or a light chain variable region including the framework fragment, or an antibody including the heavy chain variable region or the light chain variable region does not induce or prevents formation of disulfide bonds between antibody molecules while maintaining activity and reactivity of the antibody. The antibody introduced with cysteine or an antigen-binding fragment thereof easily binds with a conjugation compound such as a chemotherapeutic drug, an enzyme, an aptamer, a toxin, an affinity ligand, or a detection label, thereby being applied to various fields for diagnosis or treatment of diseases.

Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides which are useful as human or animal therapeutic agents, and which comprise increased anti-inflammatory properties and improved FcyRIIb binding.

Abstract: A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA 1a within 72 hours after delivery in the first non-compatible pregnancy.

Abstract: The present invention is directed to heterodimeric antibodies that bind CD3 and CD38.

Abstract: The present disclosure relates to antibodies specific for urokinase-type plasminogen activator (uPA). According to certain embodiments, the anti-uPA antibody specifically binds to the active form of uPA. In certain aspects, the anti-uPA antibody that specifically binds to active uPA binds specifically to the active form of human uPA (e.g., the antibody does not cross-react with active forms of uPA from non-human organisms). In certain aspects, an anti-uPA antibody of the present disclosure competes for specific binding to uPA with plasminogen activator inhibitor type 1 (PAI-1), where binding of the antibody to uPA results in internalization of a complex that includes the antibody, uPA, and urokinase-type plasminogen activator receptor (uPAR). Also provided are antibodies that specifically bind to uPA and compete for binding to uPA with a synthetic ligand of uPA. The disclosure also provides anti-uPA antibody conjugates and compositions (e.g.

Abstract: The invention provides NSP4 inhibitors (such as anti-NSP4 antibodies) and methods of using the same.

Abstract: An anthropogenic insect-resistant gene having a nucleotide sequence represented by SEQ ID NO.1, and a Cry1C toxin idiotype single-chain antibody encoded by said anthropogenic insect-resistant gene and having an amino acid sequence represented by SEQ ID NO.2; the antibody is a ?-type and has insecticidal activity, and after expression by the prokaryotic system, the primary culture thereof has binding activity to Cnaphalocrocis medinalis midgut peritrophic membrane specific receptor BBMV; the ?-type Cry1C toxin idiotype single-chain antibody of the present invention is obtained without animal immunisation, has a short preparation period and small amino acid sequence, and is suitable for large-scale in vitro production.

Abstract: An isolated anti-carboxyethylpyrrole (anti-CEP) antibody or antigen binding portion thereof includes a heavy chain variable domain that includes three CDRs having at least 90% sequence identity to the three heavy chain CDRs of SEQ ID NO: 7, and a light chain variable domain that includes three CDRs having at least 90% sequence identity to the three light chain CDRs of SEQ ID NO: 8.

Abstract: Methods for the cross-metathesis of polysaccharides with one or more olefin-terminated side chains and cross-metathesized products are described. In an exemplary embodiment, a method for the synthesis of cellulose co-carboxyesters via olefin cross-metathesis is described. Conditions of the reactions were relatively mild and the olefin-substituted polysaccharides and the appropriate monomeric olefin partners appear to follow Grubbs rules as summarized herein. The compounds and methods may be useful for structure-property studies, particularly those aimed at developing polymers for drug delivery, such as for controlled-release drug delivery systems, controlled-release coatings, increasing bioavailability of drugs, and maintaining drug supersaturation in the GI tract.

Abstract: Reversibly crosslinked, water-soluble cellulose ethers having at least two different ether components is disclosed. At least one ether component is an alkyl, hydroxyalkyl or carboxymethyl group and at least one is an alkyl group having an aldehyde function which forms hydrolyzable hemiacetals with free OH groups of the cellulose ether. The cellulose ethers are obtainable by selective oxidation of cellulose ethers containing alkyl groups having vicinal OH groups (glycol cleavage). Preferably, water-soluble cellulose ethers are co-etherified simultaneously or subsequently with 2,3-epoxypropanol (glycidol) or 3-chloro-1,2-propanediol and the 2,3-dihydroxypropyl ether groups converted entirely or partly into 2-oxoethyl ether groups by oxidation. Suitable oxidants include periodate, periodic acid or lead tetraacetate. After washing and drying, cellulose ethers reversibly crosslinked via hemiacetals can be dispersed in water or aqueous solutions, going into solution homogeneously with a time delay.

Abstract: The present invention discloses a cellulose derivative shown as formula (I), which is obtained as follows: the hydroxyl at position 6 of microcrystalline cellulose is protected with triphenylchloromethane, and then reacted with acyl chloride or isocyanate. After the protection of the hydroxyl at positions 2 and 3 of microcrystalline cellulose, triphenylmethyl is removed under acidic conditions to expose the hydroxyl at position 6. Finally, the hydroxyl at position 6 is chiral derivatized with amino acid acyl chloride or polypeptide acyl chloride, to obtain a micro chiral regulation cellulose derivative. The micro chiral regulation cellulose derivative thus obtained is coated onto the surface of a silica gel support, to form a chiral stationary phase, which is filled in a stainless steel column to form a chiral column for the separation of various different types of chiral compounds. The preparation method of the present invention is not only efficient and convenient, but also safe and reliable.

Abstract: A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron (III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between 5 and 20, and when a mixture of several maltodextrins is applied, the dextrose equivalent of the mixture lies between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture lies between 2 and 40, a process for its production and a medicament for the treatment and prophylaxis of iron deficiency conditions.

Abstract: A heparan sulphate that binds vitronectin is disclosed.

Abstract: A system and method for a polyolefin reactor temperature control system having a first reactor temperature control path, a second reactor temperature control path, and a shared temperature control path. The shared temperature control path is configured to combine and process coolant return streams, and to provide coolant supply for the first reactor temperature control path and the second reactor temperature control path.

Abstract: A curable composition for photoimprint at least includes a polymerizable compound component (A) and a photopolymerization initiator component (B) and satisfies expression (1) and (2): 0.800?Er10/Er200??(1) 2.55?Er10??(2) wherein, Er10 represents the reduced modulus (GPa) of a photocured film prepared by exposing a film of the curable composition for photoimprint to light of 10 mJ/cm2; and Er200 represents the reduced modulus (GPa) of a photocured film prepared by exposing a film of the curable composition for photoimprint to light of 200 mJ/cm2.

Abstract: Described are reagents that generate a chemical species initiating a polymerization of at least one kind of monomer by non-resonant multi-photon excitation of the reagent.